Lactobacillus gasseri BNR17 and Reduced Abdominal Pain

Research synthesisModerate evidenceModerate effect3 studies · 3 beneficial · 0 neutral · 0 harmful

Across 3 randomized controlled trials, all reported beneficial moderate-to-large effects of Lactobacillus gasseri BNR17 on reducing abdominal pain. Studies involved women with functional constipation and adults with irritable bowel syndrome (IBS), with total sample sizes ranging from 24 to 55. Evidence consistently shows improvement, but dose and form information is lacking.

Studied populations: adults with constipation or irritable bowel syndrome

Caveats: Small sample sizes (24–55) and lack of dose/form reporting limit generalizability. All studies are RCTs but require replication in larger populations.

Generated May 11, 2026

3 of 3 papers

Therapeutic Value of Lactobacillus gasseri 345A in Chronic Constipation.
- 2025-03-03
- RCT · n = 40
- Neurogastroenterology and motility 37(5)
- - Stefan Roos
  - Atti-La Dahlgren
  - Yu-Kang Mao
  - Anton Pallin
  - Andrew M Stanisz
  - Paul Forsythe
  - Wolfgang Kunze
  - Per M Hellström
- PubMed: 40033155
- DOI: 10.1111/nmo.70012
3 Insights on
- Reduced Abdominal Pain
- High evidence
"Lactobacillus gasseri showed a significant reduction in abdominal pain"
Effect
Beneficial
Effect size
Moderate
Significant
Yes
A double blind, placebo-controlled, randomized clinical trial that breast milk derived-Lactobacillus gasseri BNR17 mitigated diarrhea-dominant irritable bowel syndrome
- 2020-09-30
- RCT · n = 24
- Journal of Clinical Biochemistry and Nutrition 62(2)
- - S. Shin
  - Yoon Mi Choi
  - W. Kim
  - S. Hong
  - Jong‐Min Park
  - Joohee Kim
  - O. Kwon
  - E. Lee
  - K. Hahm
- PubMed: 29610559
- DOI: 10.3164/jcbn.17-73
9 Insights on
- Reduced Abdominal Pain
- High evidence
- Rigorous Journal
Health related-QOL analysis showed significant improvement of abdominal pain, distension, disturbed daily life, and mean defecation frequency with BNR17.
Effect
Beneficial
Effect size
Moderate
Significant
Yes
Effect of Lactobacillus gasseri BNR17 on irritable bowel syndrome: a randomized, double-blind, placebo-controlled, dose-finding trial
- 2017-12-12
- RCT · n = 55
- Food Science and Biotechnology 27(3)
- - J. Y. Kim
  - Y. Park
  - H. Lee
  - M. Park
  - O. Kwon
- PubMed: 30263811
- DOI: 10.1007/s10068-017-0296-7
3 Insights on
- Reduced Abdominal Pain
- High evidence
Among IBS symptoms scores, abdominal pain score was significantly reduced in BNR-H group.
Effect
Beneficial
Effect size
Large
Significant
Yes

Lactobacillus gasseri BNR17 and Reduced Abdominal Pain

Therapeutic Value of Lactobacillus gasseri 345A in Chronic Constipation.

A double blind, placebo-controlled, randomized clinical trial that breast milk derived-Lactobacillus gasseri BNR17 mitigated diarrhea-dominant irritable bowel syndrome

Effect of Lactobacillus gasseri BNR17 on irritable bowel syndrome: a randomized, double-blind, placebo-controlled, dose-finding trial